NeoGenomics has integrated its oncology testing portfolio with Epic Aura, allowing physicians nationwide to order tests and view results within the Epic EHR system, aiming to streamline workflows and expand test adoption, according to the company.
Optical genome mapping detected clinically significant genetic variants missed by standard tests in nearly 20% of acute leukemia cases, according to a 200-patient study.
The clearance of the Onclarity HPV Self-Collection Kit and approval of the BD Onclarity HPV Assay aim to reduce barriers for unscreened populations.
Presentations at AACR 2026 will showcase fragmentomics-based technology for detecting therapeutic markers and providing prognostic insight.
The high-throughput host-response assay provides results in approximately 20 minutes to help guide treatment decisions and antimicrobial stewardship.
Research indicates that apolipoprotein B testing outperforms standard LDL cholesterol tests in predicting risk and guiding therapy.
The Elecsys NfL test measures a protein associated with nerve cell injury to monitor disease activity in patients with relapsing remitting multiple sclerosis.
The ACC, AHA, and nine other associations have issued an updated dyslipidemia guideline, recommending earlier intervention and expanded use of lipoprotein(a) and apolipoprotein B testing to improve cardiovascular risk assessment.
Researchers at the University of East Anglia report that gut-derived blood markers may help detect early cognitive decline before symptoms, according to findings published in Gut Microbes.
Researchers at UC San Diego have developed the MAPI score, a blood test using five standard lab values to distinguish alcohol-related liver injury from metabolic causes, according to a study in Gastroenterology.
Insight Molecular Diagnostics has completed clinical validation and received ISO 13485 certification for its GraftAssureDx kidney transplant rejection test kit, moving toward FDA submission, according to the company.
The Cystic Fibrosis Base assay has received IVDR accreditation, ensuring high standards for detecting cystic fibrosis mutations.
A multicenter, vignette-based study found that adding a rapid sepsis test result to standard clinical data changed or reinforced diagnostic decisions in 86% of cases.